Sandbox/01: Difference between revisions

Jump to navigation Jump to search
No edit summary
mNo edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{PAGENAME}}
{{CMG}}; {{AE}} {{Ammu}}
{{CMG}}


{{SK}}
{{SK}} MEN type 4; MEA type 4; Multiple endocrine neoplasms type 4; Multiple endocrine adenomatosis type 4


==[[{{PAGENAME}} overview|Overview]]==
== Overview ==
Multiple endocrine neoplasia type 4 is a type of [[tumor]] that arises from [[endocrine]] cells of [[parathyroid]] gland and [[pituitary]] gland. Multiple endocrine neoplasia type 4 is part of the broad group of [[disease]]s called [[multiple endocrine neoplasia]]. Heterozygous [[mutation]] of ''Cdkn1b/CDKN1B'' [[gene]] on [[chromosome]] 12p13 is suspected to be the cause of multiple endocrine neoplasia type 4. Multiple endocrine neoplasia type 4 must be differentiated from other hereditary tumors such as [[medullary thyroid carcinoma]], C-cell hyperplasia, [[von Hippel Lindau syndrome]], familial hyperparathyroidism, [[acromegaly]], [[multiple endocrine neoplasia type 1]] (MEN 1), [[multiple endocrine neoplasia type 2a]], and [[multiple endocrine neoplasia type 2b]]. The most potent risk factor in the development of multiple endocrine neoplasia type 4 is family history. There is insufficient evidence to recommend routine screening for multiple endocrine neoplasia type 4. The most common symptoms of multiple endocrine neoplasia type 4 include [[lethargy]], [[constipation]], and [[headache]]. Transsphenoidal surgery is used for treating [[pituitary adenoma]] of multiple endocrine neoplasia type 4.


==[[{{PAGENAME}} historical perspective|Historical Perspective]]==
==Historical Perspective==
* Historical background of multiple endocrine neoplasia type 4 is given in the table below.


==[[{{PAGENAME}} classification|Classification]]==
<br>
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
|+'''''MEN IV Historical Background'''''
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Years}}
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Scientist}}
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Contribution}}
|-
! style="background: #DCDCDC;" |2006
! style="background: #F5F5F5;" |Pellegata
| style="padding: 5px 5px; background: #F5F5F5;" |Reported a case study of a patient with [[multiple endocrine neoplasia type 1]] like features such as [[acromegaly]], [[pituitary tumor]], and primary [[hyperparathyroidism]]
|-
! style="background: #DCDCDC;" |2007
! style="background: #F5F5F5;" |Georgitsi
| style="padding: 5px 5px; background: #F5F5F5;" |Reported a case study of a female with small cell neuro endocrine tumor, [[pituitary adenoma]], and [[hyperparathyroidism]]
|-
! style="background: #DCDCDC;" |2010
! style="background: #F5F5F5;" |Molatore
| style="padding: 5px 5px; background: #F5F5F5;" |Reported a case study of a female with bronchial [[carcinoid]], [[pituitary adenoma]], [[parathyroid adenoma]], and papillary thyroid carcinoma
|-
! style="background: #DCDCDC;" |2012
! style="background: #F5F5F5;" |Malanga
| style="padding: 5px 5px; background: #F5F5F5;" |Reported a case study of a female with gastric [[carcinoid tumor]] and [[hyperparathyroidism]]
|-
! style="background: #DCDCDC;" |2014
! style="background: #F5F5F5;" |Toneli
| style="padding: 5px 5px; background: #F5F5F5;" |Reported a case study of a female with [[hyperparathyroidism]] and gastrointestinal [[neuroendocrine tumor]]
|}


==[[{{PAGENAME}} pathophysiology|Pathophysiology]]==
== Pathophysiology==
Multiple endocrine neoplasia type 4 is a rare genetic disease which is the latest addition to the family of multiple endocrine neoplasia. It is characterized by [[parathyroid adenoma]] and [[pituitary adenoma]].<ref name="pmid23933118">{{cite journal| author=Thakker RV| title=Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). | journal=Mol Cell Endocrinol | year= 2014 | volume= 386 | issue= 1-2 | pages= 2-15 | pmid=23933118 | doi=10.1016/j.mce.2013.08.002 | pmc=PMC4082531 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23933118  }} </ref>


==[[{{PAGENAME}} causes|Causes]]==
=== Genetics ===
* Multiple endocrine neoplasia type 4 is an [[autosomal dominant]] disorder caused by genetic [[mutation]] of ''Cdkn1b/CDKN1B'' gene.
* The chromosome involved in the development of the disease is 12p13.
* A tumor supressor protein called p27Kip1 is encoded by ''Cdkn1b/CDKN1B'' gene germline mutation.
* The [[protein]] is derived from a cell cycle inhibitor [[p27 (gene)|''p27'']].
* The mechanism of action of the [[gene]] is to inhibit [[Cyclin-dependent kinase|cyclin/cyclin-dependent kinase]] complexes.
* Inhibition of [[Cyclin-dependent kinase|cyclin/cyclin-dependent kinase]] complexes causes cessation of cell cycle progression.<ref name="LeePellegata2013">{{cite journal|last1=Lee|first1=Misu|last2=Pellegata|first2=Natalia S.|title=Multiple Endocrine Neoplasia Type 4|volume=41|year=2013|pages=63–78|issn=0301-3073|doi=10.1159/000345670}}</ref>


==[[{{PAGENAME}} differential diagnosis|Differentiating {{PAGENAME}} from other Diseases]]==
=== Associated Conditions===
* Gastric [[carcinoid syndrome]]
* [[Uterine fibroids]]
* [[Adrenal tumor|Adrenal mass]]
* [[Zollinger-Ellison syndrome]]
* [[Gastrinoma]]
* [[Acromegaly]]
* [[Cushing's syndrome]]
* [[Neuroendocrine tumor]]s of [[cervix]]


==[[{{PAGENAME}} epidemiology and demographics|Epidemiology and Demographics]]==
==Causes==
* Heterozygous mutation of ''Cdkn1b/CDKN1B'' gene on chromosome 12p13 is suspected to be the cause of multiple endocrine neoplasia type 4.<ref name="pmid23652671">{{cite journal| author=Lee M, Pellegata NS| title=Multiple endocrine neoplasia type 4. | journal=Front Horm Res | year= 2013 | volume= 41 | issue=  | pages= 63-78 | pmid=23652671 | doi=10.1159/000345670 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23652671  }} </ref>


==[[{{PAGENAME}} risk factors|Risk Factors]]==  
==Differentiating Multiple endocrine neoplasia type 4 from other Diseases==
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center
|valign=top|
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Disease}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Definition}}
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Multiple endocrine neoplasia type 1]] ([[MEN 1]])
| style="padding: 5px 5px; background: #F5F5F5;" |An [[autosomal dominant]] genetic disorder causing [[tumor]]s of [[parathyroid]], [[pancreas]], and [[pituitary gland]].
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Multiple endocrine neoplasia type 2]]
| style="padding: 5px 5px; background: #F5F5F5;" |An [[autosomal dominant]] disorder characterized by [[medullary thyroid carcinoma]] (MTC), [[pheochromocytoma]], and primary [[hyperparathyroidism]].
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[von Hippel-Lindau syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |An [[autosomal dominant]] genetic disorder causing abnormal growth of [[blood vessel]]s in different parts of the [[body]].
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Medullary thyroid carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Medullary thyroid cancer]] (MTC) is a form of [[thyroid carcinoma]] which originates from the [[parafollicular cell]]s ([[C cell]]s), which produce the [[hormone]] [[calcitonin]].
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |C-cell hyperplasia
| style="padding: 5px 5px; background: #F5F5F5;" |C-cell hyperplasia is a form of [[thyroid]] disease which originates from the [[parafollicular cell]]s ([[C cell]]s), which produce the [[hormone]] [[calcitonin]].
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Familial hyperparathyroidism
| style="padding: 5px 5px; background: #F5F5F5;" |A [[disorder]] due to excess production of [[parathyroid]] hormone characterized by  [[kidney stone]]s, [[hypercalcemia]], [[constipation]], [[peptic ulcer]]s, and [[depression]].
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Acromegaly]]
| style="padding: 5px 5px; background: #F5F5F5;" |A rare syndrome due to excess [[growth hormone]] characterized by enlargement of the [[hand]]s, [[feet]], [[nose]], [[lip]]s, [[ear]]s, general thickening of the [[skin]], [[hypertrichosis]], [[hyperpigmentation]], [[hyperhidrosis]], and [[carpal tunnel syndrome]].
|-
| style="padding: 5px 5px; background: #F5F5F5;" colspan="2"|<small>Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). ''Mol Cell Endocrinol''. 2014;386(1-2):2-15.<ref name="pmid23933118">{{cite journal| author=Thakker RV| title=Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). | journal=Mol Cell Endocrinol | year= 2014 | volume= 386 | issue= 1-2 | pages= 2-15 | pmid=23933118 | doi=10.1016/j.mce.2013.08.002 | pmc=PMC4082531 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23933118  }} </ref> </small>
|}


==[[{{PAGENAME}} screening|Screening]]==  
== Epidemiology and Demographics ==
* It is a very rare disease. So far only 12 index cases have been reported and the prevalence of the disease is estimated to be less than 1 in 100,000.


==[[{{PAGENAME}} natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
===Age===
* The age of onset of [[tumor]] is variable.
* [[Pituitary  tumor]]s are reported from 3rd decade.
* [[Parathyroid adenoma|Parathyroid tumor]]s are reported from 4th decade of life.


==Diagnosis==
===Gender===
[[{{PAGENAME}} history and symptoms|History and Symptoms]] | [[{{PAGENAME}} physical examination|Physical Examination]] | [[{{PAGENAME}} laboratory findings|Laboratory Findings]] | [[{{PAGENAME}} electrocardiogram|Electrocardiogram]] |[[{{PAGENAME}} chest x ray|Chest X Ray]] | [[{{PAGENAME}} CT|CT]] | [[{{PAGENAME}} MRI|MRI]] | [[{{PAGENAME}} echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[{{PAGENAME}} other imaging findings|Other Imaging Findings]] | [[{{PAGENAME}}other diagnostic studies|Other Diagnostic Studies]]
* Females are more affected than males.


==Treatment==
== Risk Factors ==
[[{{PAGENAME}} medical therapy|Medical Therapy]] | [[{{PAGENAME}} surgery|Surgery]] | [[{{PAGENAME}} primary prevention|Primary Prevention]] | [[{{PAGENAME}}secondary prevention|Secondary Prevention]] | [[{{PAGENAME}} cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[{{PAGENAME}} future or investigational therapies|Future or Investigational Therapies]]
The most potent risk factor in the development of multiple endocrine neoplasia type 4 is family history of pituitary tumors and parathyroid tumors.


==Case Studies==
== Natural History, Complications and Prognosis==
[[{{PAGENAME}} case study one|Case #1]]
There is no established comments on the prognosis of multiple endocrine neoplasia type 4.


==Related Chapters==
== Diagnosis ==  
There is no established criteria for the diagnosis of multiple endocrine neoplasia type 4.
 
=== Symptoms ===
* [[Lethargy]]
* [[Depression]]
* [[Constipation]]
* [[Headache]]
 
== Treatment ==
=== Surgery and Device Based Therapy ===
* Transsphenoidal surgery is used for treating [[pituitary adenoma]] of multiple endocrine neoplasia type 4.
 
==References==
{{Reflist|2}}
 
{{WikiDoc Sources}}
[[Category:Oncology]]
[[Category:Disease]]

Revision as of 19:13, 1 June 2016

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Synonyms and keywords: MEN type 4; MEA type 4; Multiple endocrine neoplasms type 4; Multiple endocrine adenomatosis type 4

Overview

Multiple endocrine neoplasia type 4 is a type of tumor that arises from endocrine cells of parathyroid gland and pituitary gland. Multiple endocrine neoplasia type 4 is part of the broad group of diseases called multiple endocrine neoplasia. Heterozygous mutation of Cdkn1b/CDKN1B gene on chromosome 12p13 is suspected to be the cause of multiple endocrine neoplasia type 4. Multiple endocrine neoplasia type 4 must be differentiated from other hereditary tumors such as medullary thyroid carcinoma, C-cell hyperplasia, von Hippel Lindau syndrome, familial hyperparathyroidism, acromegaly, multiple endocrine neoplasia type 1 (MEN 1), multiple endocrine neoplasia type 2a, and multiple endocrine neoplasia type 2b. The most potent risk factor in the development of multiple endocrine neoplasia type 4 is family history. There is insufficient evidence to recommend routine screening for multiple endocrine neoplasia type 4. The most common symptoms of multiple endocrine neoplasia type 4 include lethargy, constipation, and headache. Transsphenoidal surgery is used for treating pituitary adenoma of multiple endocrine neoplasia type 4.

Historical Perspective

  • Historical background of multiple endocrine neoplasia type 4 is given in the table below.


MEN IV Historical Background
Years Scientist Contribution
2006 Pellegata Reported a case study of a patient with multiple endocrine neoplasia type 1 like features such as acromegaly, pituitary tumor, and primary hyperparathyroidism
2007 Georgitsi Reported a case study of a female with small cell neuro endocrine tumor, pituitary adenoma, and hyperparathyroidism
2010 Molatore Reported a case study of a female with bronchial carcinoid, pituitary adenoma, parathyroid adenoma, and papillary thyroid carcinoma
2012 Malanga Reported a case study of a female with gastric carcinoid tumor and hyperparathyroidism
2014 Toneli Reported a case study of a female with hyperparathyroidism and gastrointestinal neuroendocrine tumor

Pathophysiology

Multiple endocrine neoplasia type 4 is a rare genetic disease which is the latest addition to the family of multiple endocrine neoplasia. It is characterized by parathyroid adenoma and pituitary adenoma.[1]

Genetics

  • Multiple endocrine neoplasia type 4 is an autosomal dominant disorder caused by genetic mutation of Cdkn1b/CDKN1B gene.
  • The chromosome involved in the development of the disease is 12p13.
  • A tumor supressor protein called p27Kip1 is encoded by Cdkn1b/CDKN1B gene germline mutation.
  • The protein is derived from a cell cycle inhibitor p27.
  • The mechanism of action of the gene is to inhibit cyclin/cyclin-dependent kinase complexes.
  • Inhibition of cyclin/cyclin-dependent kinase complexes causes cessation of cell cycle progression.[2]

Associated Conditions

Causes

  • Heterozygous mutation of Cdkn1b/CDKN1B gene on chromosome 12p13 is suspected to be the cause of multiple endocrine neoplasia type 4.[3]

Differentiating Multiple endocrine neoplasia type 4 from other Diseases

Disease Definition
Multiple endocrine neoplasia type 1 (MEN 1) An autosomal dominant genetic disorder causing tumors of parathyroid, pancreas, and pituitary gland.
Multiple endocrine neoplasia type 2 An autosomal dominant disorder characterized by medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism.
von Hippel-Lindau syndrome An autosomal dominant genetic disorder causing abnormal growth of blood vessels in different parts of the body.
Medullary thyroid carcinoma Medullary thyroid cancer (MTC) is a form of thyroid carcinoma which originates from the parafollicular cells (C cells), which produce the hormone calcitonin.
C-cell hyperplasia C-cell hyperplasia is a form of thyroid disease which originates from the parafollicular cells (C cells), which produce the hormone calcitonin.
Familial hyperparathyroidism A disorder due to excess production of parathyroid hormone characterized by kidney stones, hypercalcemia, constipation, peptic ulcers, and depression.
Acromegaly A rare syndrome due to excess growth hormone characterized by enlargement of the hands, feet, nose, lips, ears, general thickening of the skin, hypertrichosis, hyperpigmentation, hyperhidrosis, and carpal tunnel syndrome.
Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1-2):2-15.[1]

Epidemiology and Demographics

  • It is a very rare disease. So far only 12 index cases have been reported and the prevalence of the disease is estimated to be less than 1 in 100,000.

Age

Gender

  • Females are more affected than males.

Risk Factors

The most potent risk factor in the development of multiple endocrine neoplasia type 4 is family history of pituitary tumors and parathyroid tumors.

Natural History, Complications and Prognosis

There is no established comments on the prognosis of multiple endocrine neoplasia type 4.

Diagnosis

There is no established criteria for the diagnosis of multiple endocrine neoplasia type 4.

Symptoms

Treatment

Surgery and Device Based Therapy

  • Transsphenoidal surgery is used for treating pituitary adenoma of multiple endocrine neoplasia type 4.

References

  1. 1.0 1.1 Thakker RV (2014). "Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)". Mol Cell Endocrinol. 386 (1–2): 2–15. doi:10.1016/j.mce.2013.08.002. PMC 4082531. PMID 23933118.
  2. Lee, Misu; Pellegata, Natalia S. (2013). "Multiple Endocrine Neoplasia Type 4". 41: 63–78. doi:10.1159/000345670. ISSN 0301-3073.
  3. Lee M, Pellegata NS (2013). "Multiple endocrine neoplasia type 4". Front Horm Res. 41: 63–78. doi:10.1159/000345670. PMID 23652671.

Template:WikiDoc Sources